This rapid chromatographic immunoassay detects the Nucleocapsid protein of SARS-CoV-2, the pathogen causing the COVID-19 disease. The test kit works with nasopharyngeal patient swabs and includes all required materials for sample collection and testing. No equipment is needed and the results are available in 15 minutes.
As the second wave of COVID-19 infections has assumed unprecedented proportions in terms of sheer numbers, the TAT of traditional PCR tests cannot solely match the current challenge. We strongly believe that the Convergys® COVID-19 Rapid Antigen Test is set to assume great importance and priority in quick screening and isolating the COVID-19 cases.
Convergent Technologies and the Fight against COVID-19
Convergent Technologies has been at the forefront in the fight against COVID-19 right from the onset of Pandemic.
Starting with the launch in March 2020 of POC RT-PCR, a fully-integrated system from the viral RNA extraction to onsite reference and central lab-grade results in real-time, Convergent has been a trusted partner in quick and reliable patient triage, isolation and therapy management solutions. Thousands of these tests have been successfully deployed in many clinical and corporate settings. The systems are also currently in use by many Tourism Organizations, National Defence, Critical Support Infrastructures and NGOs in EU and other geographies.
We truly believe that the rapid antigen detection tests shall be a great addition to our armour of powerful Convergys range of diagnostic tools in helping negotiate the challenges presented by second wave of Coronavirus cases.